Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Exceso de peso en España: situación actual, proyecciones para 2030 y sobrecoste directo estimado para el Sistema Nacional de Salud, Excess weight in Spain: current situation, projections for 2030, and estimated direct extra cost for the Spanish Health System

  • Hernáez, Álvaro
  • Zomeño, M. Dolores
  • Degano, Irene R.
  • Pérez Fernández, Sílvia
  • Goday, Alberto
  • Vila, Joan
  • Civeira, Fernando
  • Moure, Ricardo
  • Marrugat, Jaume
Introducción y objetivos El exceso de peso potencia algunas enfermedades crónicas y reduce la calidad de vida, y su prevalencia crece en todo el mundo. El objetivo es estimar la evolución del exceso de peso entre 1987 y 2014 en población española adulta, calcular los casos de exceso de peso y sus sobrecostes médicos directos en 2006 y 2016, y proyectar su tendencia a 2030. Métodos Se seleccionaron 47 artículos en una búsqueda bibliográfica sistemática para determinar la progresión de las prevalencias de sobrepeso, obesidad y obesidad mórbida y del índice de masa corporal promedio entre 1987 y 2014. Con estos datos, se estimó el número de casos en adultos españoles en 2006, 2016 y 2030 y sus sobrecostes directos. Resultados Entre 1987 y 2014, las prevalencias de sobrepeso, obesidad y obesidad mórbida aumentaron el 0,28%/año (p=0,004), el 0,50%/año (p<0,001) y el 0,030%/año (p=0,006) en los varones y el 0,10%/año (p=0,123), el 0,25%/año (p=0,078) y el 0,042%/año (p=0,251) en las mujeres. El índice de masa corporal aumentó 0,10 puntos/año en varones (p<0,001) y 0,26 en mujeres (significativamente solo entre 1987-2002, p <0,001). Se estimaron 23.500.000 casos de exceso de peso en 2016, cuyo sobrecoste médico directo supuso 1.950.000.000 euros/año. De mantenerse la tendencia, entre 2016 y 2030 aparecerán 3.100.000 nuevos casos de exceso de peso, y se alcanzará en 2030 un sobrecoste médico directo de unos 3.000.000.000 euros/año. Conclusiones El exceso de peso en los adultos en España aumenta desde que existen registros, y en 2016 supuso un sobrecoste directo del 2% del presupuesto sanitario. Con esta tendencia, en 2030 se habrá incrementado un 16% el número de casos y un 58% su sobrecoste sanitario directo., Introduction and objectives Excess weight promotes the development of several chronic diseases and decreases quality of life. Its prevalence is increasing globally. Our aim was to estimate the trend in excess weight between 1987 and 2014 in Spanish adults, calculate cases of excess weight and its direct extra costs in 2006 and 2016, and project its trend to 2030. Methods We selected 47 articles in a systematic literature search to determine the progression of the prevalence of overweight, nonmorbid obesity, and morbid obesity and average body mass index between 1987 and 2014. We projected the expected number of cases in 2006, 2016, and 2030 and the associated direct extra medical costs. Results Between 1987 and 2014, the prevalence of overweight, obesity, and morbid obesity increased by 0.28%/y (P=.004), 0.50%/y (P <.001) and 0.030%/y (P=.006) in men, and by 0.10%/y (P=.123), 0.25%/y (P=.078), and 0.042%/y (P=.251) in women. The mean body mass index increased by 0.10 kg/m2/y in men (P <.001) and 0.26 kg/m2/y in women (significantly only between 1987 and 2002, P <.001). We estimated 23 500 000 patients with excess weight in 2016, generating 1.95 billion €/y in direct extra medical costs. If the current trend continues, between 2016 and 2030, there will be 3 100 000 new cases of excess weight, leading to 3.0 billion €/y of direct extra medical costs in 2030. Conclusions Excess weight in Spanish adults has risen since the creation of population registries, generating direct extra medical costs that represent 2% of the 2016 health budget. If this trend continues, we expect 16% more cases in 2030 and 58% more direct extra medical costs., info:eu-repo/semantics/acceptedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Increased consumption of virgin olive oil, nuts, legumes, whole grains, and fish promotes HDL functions in humans

  • Hernáez, Álvaro
  • Sanllorente Melenchon, Albert
  • Castañer, Olga
  • Martínez-González, Miguel Ángel, 1957-
  • Ros Rahola, Emilio
  • Pintó Sala, Xavier
  • Estruch Riba, Ramon
  • Salas Salvadó, Jordi
  • Corella Piquer, Dolores
  • Alonso Gómez, Ángel M.
  • Serra Majem, Lluís
  • Fiol, Miquel
  • Lapetra, José
  • Gómez-Gracia, Enrique
  • de la Torre, Rafael
  • Lamuela Raventós, Rosa Ma.
  • Fitó Colomer, Montserrat
Scope To evaluate whether increases in the consumption of cardioprotective food groups (virgin olive oil, nuts, fruits/vegetables, legumes, whole grains, fish, and wine) are associated with improvements in high-density lipoprotein (HDL) functions in high cardiovascular risk subjects. Methods and Results The association between 1-year changes in food group consumption and HDL functionality traits in 296 high cardiovascular risk subjects is assessed. Increases in virgin olive oil (10 g d–1) and whole grain consumption (25 g d–1) are associated with increments in cholesterol efflux capacity (+0.7%, P = 0.026, and +0.6%, P = 0.017, respectively). Increases in nut (30 g d–1) and legume intake (25 g d–1) are linked to increments in paraoxonase-1 activity (+12.2%, P = 0.049, and +11.7%, P = 0.043, respectively). Legume intake increases are also related to decreases in cholesteryl ester transfer protein activity (–4.8%, P = 0.028). Fish consumption increments (25 g d–1) are associated with increases in paraoxonase-1 activity (+3.9%, P = 0.030) and declines in cholesteryl ester transfer protein activity (–1.6%, P = 0.021), HDL cholesterol concentrations (–1.1%, P = 0.039), and functions related to HDL levels (cholesterol efflux capacity, –1.1%, P = 0.010). Conclusion Increases in the consumption of virgin olive oil, nuts, legumes, whole grains, and fish (achievable through a regular diet) were associated with improvements in HDL functions in high cardiovascular risk subjects., info:eu-repo/semantics/acceptedVersion
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

The Burden of Neglected HIV-2 and HTLV-1 Infections in Spain.

  • Treviño A
  • Caballero E
  • de Mendoza C
  • Aguilera A
  • Pirón M
  • Soriano V
  • Rodríguez M
  • del Romero J
  • Marcaida G
  • Ocete MD
  • Molina I
  • Aguilera A
  • Rodríguez-Calviño JJ
  • Navarro D
  • Regueiro B
  • Benito R
  • Algarate S
  • Gil J
  • Ortiz de Lejarazu R
  • Rojo S
  • Eirós JM
  • Manzardo C
  • Miró JM, García J
  • Paz I
  • Poveda E
  • Calderón E
  • Mateos M
  • Dronda F
  • Escudero D
  • Trigo M
  • Diz J
  • García-Campello M
  • Rodríguez-Iglesias M
  • Hernández-Betancor A
  • Martín AM
  • Ramos JM
  • Gimeno A
  • Gutiérrez F
  • Rodríguez JC
  • Sanchez V
  • Gómez-Hernando C
  • Cilla G
  • Pérez-Trallero E
  • López-Aldeguer J
  • Fernández-Pereira L
  • Niubó J
  • Hernández M
  • López-Lirola AM
  • Gómez-Sirvent JL
  • Force L
  • Cifuentes C
  • Pérez S
  • Morano L
  • Raya C
  • González-Praetorius A
  • Pérez JL
  • Peñaranda M
  • Hernáez-Crespo S
  • Montejo JM
  • Roc L
  • Martínez-Sapiña A
  • Viciana I
  • Cabezas T
  • Lozano A
  • Fernández JM
  • García-Bermejo I
  • Gaspar G
  • García R
  • Górgolas M
  • Vegas MC
  • Vegas C
  • Blas J
  • Miralles P
  • Aldamiz T
  • Margall N
  • Guardia C
  • Do Pico E
  • Polo I
  • Aguinaga A
  • Ezpeleta C
  • Sauleda S
  • Torres P
  • Jiménez A
  • Blanco L
  • González R
  • Suárez A
  • Requena S
  • Benítez-Gutiérrez L
  • Cuervas-Mons V
  • Barreiro P
HIV-2 and HTLV-1 infections are globally less frequent than those produced by HIV-1, the classical AIDS agent. In Spain and up to the end of 2014, a total of 310 cases of HIV-2, 274 of HTLV-1, and 776 of HTLV-2 infections had been reported. No cases of HTLV-3 or HTLV-4 infections have been identified so far in Spain. Most persons infected with HIV-2 or HTLV-1 acknowledge epidemiological risk factors for contagion, such as originating from or living in endemic regions and/or having had sexual partners from those areas. However, risk factors could not be recognized in up to 20-25% of carriers in Spain. Thus, it seems worth keeping a high level of clinical suspicion in order to identify earlier these neglected human retroviral infections, since diagnostic procedures and antiviral treatment are specific for each of these agents. In this article we summarize the major contributions reported at the meeting of the Spanish Group for HIV-2/HTLV held in Madrid in December 2014
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Exceso de peso en España: situación actual, proyecciones para 2030 y sobrecoste directo estimado para el Sistema Nacional de Salud, Excess weight in Spain: current situation, projections for 2030, and estimated direct extra cost for the Spanish Health System

  • Hernáez, Álvaro
  • Zomeño, M. Dolores
  • Degano, Irene R.
  • Pérez Fernández, Sílvia
  • Goday, Alberto
  • Vila, Joan
  • Civeira, Fernando
  • Moure, Ricardo
  • Marrugat, Jaume
Introducción y objetivos El exceso de peso potencia algunas enfermedades crónicas y reduce la calidad de vida, y su prevalencia crece en todo el mundo. El objetivo es estimar la evolución del exceso de peso entre 1987 y 2014 en población española adulta, calcular los casos de exceso de peso y sus sobrecostes médicos directos en 2006 y 2016, y proyectar su tendencia a 2030. Métodos Se seleccionaron 47 artículos en una búsqueda bibliográfica sistemática para determinar la progresión de las prevalencias de sobrepeso, obesidad y obesidad mórbida y del índice de masa corporal promedio entre 1987 y 2014. Con estos datos, se estimó el número de casos en adultos españoles en 2006, 2016 y 2030 y sus sobrecostes directos. Resultados Entre 1987 y 2014, las prevalencias de sobrepeso, obesidad y obesidad mórbida aumentaron el 0,28%/año (p=0,004), el 0,50%/año (p<0,001) y el 0,030%/año (p=0,006) en los varones y el 0,10%/año (p=0,123), el 0,25%/año (p=0,078) y el 0,042%/año (p=0,251) en las mujeres. El índice de masa corporal aumentó 0,10 puntos/año en varones (p<0,001) y 0,26 en mujeres (significativamente solo entre 1987-2002, p <0,001). Se estimaron 23.500.000 casos de exceso de peso en 2016, cuyo sobrecoste médico directo supuso 1.950.000.000 euros/año. De mantenerse la tendencia, entre 2016 y 2030 aparecerán 3.100.000 nuevos casos de exceso de peso, y se alcanzará en 2030 un sobrecoste médico directo de unos 3.000.000.000 euros/año. Conclusiones El exceso de peso en los adultos en España aumenta desde que existen registros, y en 2016 supuso un sobrecoste directo del 2% del presupuesto sanitario. Con esta tendencia, en 2030 se habrá incrementado un 16% el número de casos y un 58% su sobrecoste sanitario directo., Introduction and objectives Excess weight promotes the development of several chronic diseases and decreases quality of life. Its prevalence is increasing globally. Our aim was to estimate the trend in excess weight between 1987 and 2014 in Spanish adults, calculate cases of excess weight and its direct extra costs in 2006 and 2016, and project its trend to 2030. Methods We selected 47 articles in a systematic literature search to determine the progression of the prevalence of overweight, nonmorbid obesity, and morbid obesity and average body mass index between 1987 and 2014. We projected the expected number of cases in 2006, 2016, and 2030 and the associated direct extra medical costs. Results Between 1987 and 2014, the prevalence of overweight, obesity, and morbid obesity increased by 0.28%/y (P=.004), 0.50%/y (P <.001) and 0.030%/y (P=.006) in men, and by 0.10%/y (P=.123), 0.25%/y (P=.078), and 0.042%/y (P=.251) in women. The mean body mass index increased by 0.10 kg/m2/y in men (P <.001) and 0.26 kg/m2/y in women (significantly only between 1987 and 2002, P <.001). We estimated 23 500 000 patients with excess weight in 2016, generating 1.95 billion €/y in direct extra medical costs. If the current trend continues, between 2016 and 2030, there will be 3 100 000 new cases of excess weight, leading to 3.0 billion €/y of direct extra medical costs in 2030. Conclusions Excess weight in Spanish adults has risen since the creation of population registries, generating direct extra medical costs that represent 2% of the 2016 health budget. If this trend continues, we expect 16% more cases in 2030 and 58% more direct extra medical costs., info:eu-repo/semantics/acceptedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Increased consumption of virgin olive oil, nuts, legumes, whole grains, and fish promotes HDL functions in humans

  • Hernáez, Álvaro
  • Sanllorente Melenchon, Albert
  • Castañer, Olga
  • Martínez-González, Miguel Ángel, 1957-
  • Ros Rahola, Emilio
  • Pintó Sala, Xavier
  • Estruch Riba, Ramon
  • Salas Salvadó, Jordi
  • Corella Piquer, Dolores
  • Alonso Gómez, Ángel M.
  • Serra Majem, Lluís
  • Fiol, Miquel
  • Lapetra, José
  • Gómez-Gracia, Enrique
  • de la Torre, Rafael
  • Lamuela Raventós, Rosa Ma.
  • Fitó Colomer, Montserrat
Scope To evaluate whether increases in the consumption of cardioprotective food groups (virgin olive oil, nuts, fruits/vegetables, legumes, whole grains, fish, and wine) are associated with improvements in high-density lipoprotein (HDL) functions in high cardiovascular risk subjects. Methods and Results The association between 1-year changes in food group consumption and HDL functionality traits in 296 high cardiovascular risk subjects is assessed. Increases in virgin olive oil (10 g d–1) and whole grain consumption (25 g d–1) are associated with increments in cholesterol efflux capacity (+0.7%, P = 0.026, and +0.6%, P = 0.017, respectively). Increases in nut (30 g d–1) and legume intake (25 g d–1) are linked to increments in paraoxonase-1 activity (+12.2%, P = 0.049, and +11.7%, P = 0.043, respectively). Legume intake increases are also related to decreases in cholesteryl ester transfer protein activity (–4.8%, P = 0.028). Fish consumption increments (25 g d–1) are associated with increases in paraoxonase-1 activity (+3.9%, P = 0.030) and declines in cholesteryl ester transfer protein activity (–1.6%, P = 0.021), HDL cholesterol concentrations (–1.1%, P = 0.039), and functions related to HDL levels (cholesterol efflux capacity, –1.1%, P = 0.010). Conclusion Increases in the consumption of virgin olive oil, nuts, legumes, whole grains, and fish (achievable through a regular diet) were associated with improvements in HDL functions in high cardiovascular risk subjects., info:eu-repo/semantics/acceptedVersion
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Eye movement desensitization and reprocessing therapy versus supportive therapy in affective relapse prevention in bipolar patients with a history of trauma, study protocol for a randomized controlled trial

  • Moreno Alcázar, Ana|||0000-0002-3392-5590
  • Radua, Joaquim|||0000-0003-1240-5438
  • Landin-Romero, Ramon|||0000-0003-0485-8090
  • Blanco Presas, Laura|||0000-0001-6272-4416
  • Madre Rull, Mercè|||0000-0002-4660-3216
  • Reinares, María|||0000-0001-8859-4453
  • Comes, Mercè
  • Jiménez, Esther
  • Crespo, José Manuel
  • Vieta, Eduard|||0000-0002-0548-0053
  • Pérez Solà, Víctor|||0000-0002-5825-2337
  • Novo, Patricia
  • Doñate, Marta
  • Cortizo, Romina|||0000-0001-7544-8537
  • Valiente Gomez, Alicia|||0000-0003-0220-2397
  • Lupo, Walter
  • McKenna, Peter J.
  • Pomarol-Clotet, Edith|||0000-0002-8159-8563
  • Amann, Benedikt L.|||0000-0002-4407-1519
Up to 60% of patients with bipolar disorder (BD) have a history of traumatic events, which is associated with greater episode severity, higher risk of comorbidity and higher relapse rates. Trauma-focused treatment strategies for BD are thus necessary but studies are currently scarce. The aim of this study is to examine whether Eye Movement Desensitization and Reprocessing (EMDR) therapy focusing on adherence, insight, de-idealisation of manic symptoms, prodromal symptoms and mood stabilization can reduce episode severity and relapse rates and increase cognitive performance and functioning in patients with BD. This is a single-blind, randomized controlled, multicentre trial in which 82 patients with BD and a history of traumatic events will be recruited and randomly allocated to one of two treatment arms: EMDR therapy or supportive therapy. Patients in both groups will receive 20 psychotherapeutic sessions, 60 min each, during 6 months. The primary outcome is a reduction of affective episodes after 12 and 24 months in favour of the EMDR group. As secondary outcome we postulate a greater reduction in affective symptoms in the EMDR group (as measured by the Bipolar Depression Rating Scale, the Young Mania Rating Scale and the Clinical Global Impression Scale modified for BD), and a better performance in cognitive state, social cognition and functioning (as measured by the Screen for Cognitive Impairment in Psychiatry, The Mayer-Salovey-Caruso Emotional Intelligence Test and the Functioning Assessment Short Test, respectively). Traumatic events will be evaluated by The Holmes-Rahe Life Stress Inventory, the Clinician-administered PTSD Scale and the Impact of Event Scale. The results of this study will provide evidence whether a specific EMDR protocol for patients with BD is effective in reducing affective episodes, affective symptoms and functional, cognitive and trauma symptoms. The trial is registered at ClinicalTrials.gov, identifier: . Registered on 3 December 2015. The online version of this article (doi:10.1186/s13063-017-1910-y) contains supplementary material, which is available to authorized users.